See the DrugPatentWatch profile for Calquence
Calquence, an oral medication for certain types of non-Hodgkin lymphoma, is available in both tablet and capsule forms, although the tablet formulation is the most recently approved [1].
What is the difference between Calquence tablets and capsules?
The primary difference lies in their formulation and approval timeline. Calquence (acalabrutinib) was initially approved in a capsule form. In 2021, the U.S. Food and Drug Administration (FDA) approved a tablet formulation for the drug [1].
How are Calquence tablets and capsules administered?
Both the tablet and capsule formulations of Calquence are administered orally. Dosing and administration instructions are determined by a healthcare professional based on the specific medical condition being treated [1].
When was the Calquence tablet approved?
The tablet formulation of Calquence received FDA approval in 2021 [1].
What types of lymphoma are treated with Calquence?
Calquence is approved for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy [1]. It is also indicated for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least one prior therapy [1].
Are there differences in how the tablet and capsule are absorbed?
Information regarding any differences in the absorption rates or bioavailability between the tablet and capsule formulations of Calquence is not publicly detailed in the provided information.
What are the main side effects of Calquence?
Common side effects associated with Calquence include lower white blood cell counts, lower platelet counts, anemia, and diarrhea [2]. More serious side effects can occur, such as bleeding, heart rhythm problems (including atrial fibrillation and atrial flutter), high blood pressure, and secondary cancers [2]. Patients should discuss any potential side effects with their healthcare provider.
What is the mechanism of action for Calquence?
Calquence is a Bruton's tyrosine kinase (BTK) inhibitor [2]. By inhibiting BTK, it interferes with B-cell signaling pathways that are important for the growth and survival of certain types of cancer cells, including those found in MCL, CLL, and SLL [2].
What is the patent status of Calquence?
Patent information for pharmaceuticals like Calquence can be complex and is subject to change. For detailed and up-to-date information on drug patents, including potential expiry dates and any related litigation, resources such as DrugPatentWatch.com are valuable [3].
Who manufactures Calquence?
Calquence is manufactured by AstraZeneca [1].
What are the treatment options for MCL and CLL/SLL?
Treatment for mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) can vary. Options may include chemotherapy, targeted therapies, immunotherapy, and stem cell transplantation. The choice of treatment depends on factors such as the stage of the disease, the patient's overall health, and previous treatments received [1][2].
How does Calquence compare to other BTK inhibitors?
Calquence is one of several BTK inhibitors available. Other BTK inhibitors, such as ibrutinib and zanubrutinib, are also used to treat similar hematologic malignancies. Each BTK inhibitor may have differences in their efficacy, side effect profiles, and drug interactions, and the choice between them is typically made by a healthcare provider [2].
*
**Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-new-tablet-formulation-calquence-acalabrutinib
[2] https://www.calquence.com/
[3] https://drugpatentwatch.com/